Do hormone pellets permanently enlarge the clitoris? Here's what we know

What did @pagingdrfran actually say?

She made two core arguments against hormone pellets: first, that you can't remove them if side effects occur, and second, that supratherapeutic testosterone levels from pellets can cause permanent physical changes. Specifically, she claimed the clitoris "can enlarge and stay permanently large" and that voice deepening can be irreversible. She also cited a 50% side effect rate for pellets versus 14% for FDA-approved options, and noted pellets are cash-pay and not FDA-approved.

She's talking to a real audience of women considering menopause hormone therapy, and she's clearly positioning pellets as the riskier, less regulated option. The framing is pointed, but the underlying clinical concerns she raises are not invented. They're documented, even if her numbers deserve scrutiny.

Does the science back this up?

Partially, yes. The virilization risk from supratherapeutic testosterone is real and documented. The non-removability problem is also a genuine clinical limitation. But her specific percentages, 50% side effects for pellets versus 14% for FDA-approved HRT, are not sourced to a single well-powered randomized trial, and that matters.

On virilization: clitoromegaly and voice deepening from androgen excess are well-established in the medical literature. Testosterone pellets have been shown to produce highly variable serum levels. A 2012 study by Glaser and Dimitrakakis published in Maturitas found pellets effective but acknowledged significant inter-patient variability in absorption. A 2019 review by Wierman et al. in the Journal of Clinical Endocrinology and Metabolism explicitly cautioned that testosterone doses producing supraphysiologic levels in women carry virilization risks. The voice change concern has been documented in case reports and in studies of transgender men on testosterone therapy, where even short-term exposure can produce irreversible laryngeal changes. Clitoromegaly following androgen excess is also considered largely irreversible once structural changes occur.

The 50% side effect figure is harder to pin down. It likely derives from observational data or manufacturer-sponsored studies, not a clean head-to-head trial. Treat it as directionally plausible, not a settled statistic.

What did they get wrong (or right)?

She got the core clinical warnings right. The inability to titrate or remove a pellet mid-course is a real limitation compared to patches or gels, and the virilization risk from dosing errors is not hypothetical. Credit where it's due.

Where she oversimplifies: the claim that "more than 50% of patients are going to have side effects" is presented as settled fact. The data on pellet adverse event rates comes mostly from retrospective studies and proprietary company data, not rigorous randomized controlled trials. The 14% figure for FDA-approved HRT is similarly unattributed. These numbers may be in the right ballpark, but citing them without qualification is the kind of move that gets doctors in trouble on both sides of medical debates.

She also implies all FDA-approved HRT is uniformly safer, which is mostly true but glosses over the fact that oral estradiol carries its own risks, including venous thromboembolism, that transdermal routes largely avoid. FDA approval indicates a regulatory review process, not a guarantee of zero harm for every patient.

What should you actually know?

If you're considering hormone therapy for menopause symptoms, the lack of FDA approval for pellets is a real regulatory gap worth taking seriously. FDA approval means a drug has gone through standardized pharmacokinetic testing, manufacturing quality controls, and safety review. Pellets have not. That doesn't mean pellets never work, but it does mean there's less standardized data on what dose you're actually getting.

The virilization risk is not a scare tactic. Testosterone pellets implanted subcutaneously release hormone based on physical activity, blood flow, and individual metabolism, meaning two women with the same pellet can end up with very different serum levels. If your levels run high for weeks before the pellet dissolves, there is a real window for androgenic side effects to develop. Some of those effects, particularly voice changes and clitoral enlargement, may not fully reverse even after levels normalize.

The practical takeaway: if you're exploring HRT options, FDA-approved transdermal or oral formulations allow for dose adjustments. That flexibility is clinically meaningful. If you're already using pellets and experiencing symptoms of androgen excess, including acne, hair thinning, voice changes, or clitoral sensitivity changes, raise it with your provider immediately.

• Ask your provider for a serum testosterone level if you're on pellets, not just "how do you feel."
• FDA-approved options are generally covered by insurance; pellets are almost always out-of-pocket.
• The financial incentive point she raises is worth asking your own provider about directly.